Industry Insights

  1. Global Shifts And Strategic Resilience Will Shape CGT In 2026 1/7/2026

    Dr. Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, and Ali Pashazadeh, Founder of Treehill Partners share why CGT developers are now navigating a landscape defined not only by technological innovation but also by geography, regulatory agility, and investment dynamics.

  2. Sales & Operations Planning for Small Teams: Aligning Clinical Supply 1/6/2026

    Small clinical teams don’t fail at S&OP from missing systems—they fail from unclear demand and decisions. Alignment comes from discipline, shared visibility, and acting on reality before timelines slip.

  3. 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For 1/5/2026

    2026 is shaping up to be a year in which operational discipline, strategic alignment, and regulatory preparedness will differentiate high-performing sponsors from those facing avoidable delays.

  4. A Deeper Look At Pharma's Structural Supply Chain Vulnerability 12/31/2025

    Fixing limited capacity in pharmaceutical CMC development starts with understanding a complex web of root causes.

  5. Allogeneic Cell Therapy's Success Hinges On Perfecting The Platform 12/29/2025

    The industry remains far from realizing a manufacturing platform with a repeatable, standardized process that can support broad clinical and commercial deployment.

  6. Harnessing Mitochondria: A New Frontier In Therapeutic Innovation 12/26/2025

    What if we can replace damaged mitochondria with young and healthy mitochondria? In recent years, a new therapeutic field has evolved: mitochondrial transplantations.

  7. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

    By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

  8. CGT Industrialization Starts With CDMO Alignment 12/19/2025

    Fragmented processes are stalling progress. By aligning CDMOs through transparency and standards, developers can move past the COGS obsession and stabilize the supply chain.

  9. Powering Cell Therapies With RNA: A New Code For Engineered Immunity 12/19/2025

    RNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.

  10. Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost 12/18/2025

    Our recent Cell & Gene Live, Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing, explored how developers and CDMOs are navigating multi-modal manufacturing decisions, balancing cost, capacity, risk, and long-term commercial viability.